Feedback from the field is incredibly important when participating in new payment models like the Oncology Care Model, said Basit Chaudhry, MD, PhD, founder of Tuple Health.
Feedback from the field is incredibly important when participating in new payment models like the Oncology Care Model, said Basit Chaudhry, MD, PhD, founder of Tuple Health.
Transcript
With Oncology Care First being delayed at least a year now, where do you see opportunities for CMS to make some changes to the model based on the ongoing challenges practices have reported in the Oncology Care Model?
One of the things that Medicare talks about quite a bit in these payment models, particularly through CMMI [Center for Medicare and Medicaid Innovation], is that they're learning models. And I think that's the very much the right spirit. You know, these kinds of changes are so complicated, even for an entity as large as Medicare, there's no way to get it right in the beginning. So, this whole tact of making things a learning approach, I think, is really critical. And I think it's very, very important to really think, from the payer perspective, really think carefully about what did work, what did not, and I know Medicare tries to do this, and then really implement those changes. And I think one of the big things that we've seen particularly for a model as complicated as OCM, is, I think, until you're actually living it and doing it directly, it's hard to know what it's like.
So, what we really hope is that feedback from the field is one of the drivers for change and OCF in the design. So, I think taking a human-centric or user-centered design approach towards the problem would be something I'd very much recommend and hope that we see payers do more and more.
At ASCO, Testing and AI Rival Drugs for Attention, but Reimbursement Remains a Barrier
July 5th 2025Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage cancer care over time. A feature from our upcoming special issue of Evidence-Based Oncology: our annual ASCO recap.
Read More
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More